MicroRNAs act as negative regulators of gene expression by inhibiting the translation or promoting the degradation of target mRNAs. Recent studies have revealed key roles of microRNAs as regulators of the growth, development, function, and stress responsiveness of the heart, providing glimpses of undiscovered regulatory mechanisms and potential therapeutic targets for the treatment of heart disease.
gene expression through two major mechanisms, translational repression and mRNA cleavage, which depend on the extent of complementarity between the miRNA and its mRNA target and other criteria that are still being defined. Although it was originally thought that perfect base pairing was a requisite for mRNA cleavage, it has now become clear that even imperfect base pairing can lead to a decrease in target mRNA abundance originally thought that perfect base pairing was a requisite for repression and mRNA cleavage, which depend on the extent of complementarity between the miRNA and its mRNA target, forms the basis for many current target prediction models. Although increasingly sophisticated computational approaches to predict miRNAs and their targets are becoming available, target prediction remains a major challenge and requires additional high- and low-affinity mRNA targets and by the targeting of multiple miRNAs to individual mRNAs.

Blockade to miRNA processing by Dicer loss of function

The importance of miRNAs in the normal development of vertebrates is evidenced by Dicer loss of function in both zebrafish and mice (31, 32). Zebrafish lacking Dicer and thereby the capacity to synthesize miRNAs undergo relatively normal morphogenesis and organ development but die two weeks after fertilization due to a general growth arrest (32). Dicer-deficient mice die at gastrulation and lack multipotent stem cells (31). A caveat to the interpretation of these phenotypes, with respect to the requirement of miRNAs, is that Dicer may perform functions in addition to miRNA processing.

The roles of miRNAs in tissue development have also begun to be explored through conditional deletion of Dicer in specific cell lines and tissue types (33–36). To study the requirement of miRNAs in the mouse heart, a conditional Dicer allele was removed by expressing Cre recombinase under control of Nkx2.5 regulatory elements, which are expressed in the heart from day E8.5 onwards (37). Cardiac deletion of Dicer did not perturb the expression of cardiac markers of differentiation or patterning but resulted in death from cardiac failure by E12.5 due to a poorly developed ventricular myocardium (4). Since these experiments did not allow for deletion of Dicer during the earliest steps of cardiogenesis, it remains to be determined whether miRNAs play a role in specification of the cardiac lineage.

Cardiac hypertrophy and pathological remodeling

The heart responds to chronic and acute injury by hypertrophic growth. Cardiomyocyte hypertrophy is the dominant cellular response to virtually all forms of hemodynamic overload, endocrine disorders, myocardial injury, or inherited mutations in a variety of structural and contractile proteins (2, 38). Numerous signaling pathways, especially those involving aberrant calcium signaling, drive cardiac hypertrophy and pathological remodeling (39). Hypertrophic growth in response to stress involves different signaling pathways and gene expression patterns than physiological hypertrophy as occurs in response to exercise. Stress-mediated myocardial hypertrophy is a complex phenomenon associated with numerous adverse consequences with distinct molecular and histological characteristics causing the heart to dilate and decompensate which, through myocyte degeneration and death, often culminates in heart failure. As such, there has been intense interest in deciphering the underlying molecular mechanisms and in discovering novel therapeutic targets for suppressing adverse cardiac growth.

Cardiac myocytes are normally surrounded by a fine network of collagen fibers. In response to pathological stress, cardiac fibroblasts and extracellular matrix proteins accumulate disproportionately and excessively (40). Myocardial fibrosis, a characteristic of all forms of pathological hypertrophy, leads to mechanical stiffness, which contributes to contractile dysfunction (41). Another hallmark of pathological hypertrophy and heart failure is the reactivation of a set of fetal cardiac genes, including those encoding atrial natriuretic peptide, B-type natri...
uretic peptide, and fetal isoforms of contractile proteins, such as skeletal α-actin and β-myosin heavy chain (βMHC). These genes are typically repressed postnatally and replaced by the expression of a set of adult cardiac genes (42).

The consequences of fetal gene expression on cardiac function and remodeling (e.g., fibrosis) are not completely understood, but the upregulation of βMHC, a slow ATPase, and downregulation of αMHC, a fast-contracting ATPase, in response to stress has been implicated in the diminution of cardiac function (43). βMHC is the predominant myosin isoform expressed in the heart prenatally whereas αMHC is upregulated after birth. Thyroid hormone signaling soon after birth provides the stimulus for the β- to αMHC switch (44). There are differences in the relative abundance of α- and βMHC in rodent and human hearts; α represents more than 95% of MHC in the adult rodent heart whereas it constitutes only about 30% of MHC in the adult human heart (45). Nevertheless, downregulation of αMHC and upregulation of βMHC is a common response to cardiac injury irrespective of the species. Moreover, changes in the proportion of MHC isoforms correlate with the level of mechanical performance and efficiency of the heart. Relatively minor changes in the ratio of αMHC to βMHC have been shown to have profound effects on cardiac contractility in humans and rodents (43, 46–48). Thus, much attention has focused on understanding the mechanisms that regulate αMHC and βMHC switching and on potential approaches for therapeutically manipulating these mechanisms.

Regulation of cardiac hypertrophy and heart failure by stress-responsive miRNAs

In several recent studies, microarray analyses were performed to determine whether miRNAs are dysregulated in hypertrophic and failing hearts. These studies point to a collection of miRNAs that are up- and downregulated during pathological cardiac remodeling in rodents and humans (7–11). In vitro experiments using either overexpression or knockdown of miRNAs in cultured cardiomyocytes indicate that a subset of these miRNAs are indeed actively involved in cardiomyocyte hypertrophy (7–11). Intriguingly, forced expression of certain stress-inducible miRNAs in primary cardiomyocytes or in the hearts of transgenic mice is sufficient to drive hypertrophic growth and myocyte disarray (7–11). Cardiac-specific overexpression of miRNA-195 (miR-195), which is consistently upregulated in rodent and human hypertrophic hearts, for example, results in dilated cardiomyopathy and heart failure in mice as early as two weeks of age (8) (Figures 2 and 3), implying that upregulation of miR-195 during cardiac hypertrophy actively contributes to the disease process. Based on target predictions for miR-195, we speculate that the cardiac phenotype of these transgenic mice results from the downregulation of multiple prosurvival proteins by this miRNA. Since miR-195 belongs to a small family of related miRNAs, it will be interesting to investigate the potential involvement of the other family members in cardiac disease.

Another miRNA consistently induced by cardiac stress, miR-21, appears to function as a regulator of cardiac growth and fetal gene activation in primary cardiomyocytes in vitro although some confusion remains regarding its exact role (7, 10). Cheng et al. (7) reported that knockdown of miR-21 using a 2′-O-methyl-miR-21 antisense oligonucleotide in cardiomyocytes in culture can suppress cardiomyocyte growth and fetal gene expression in response to the hypertrophic agonists angiotensin II and phenylephrine. However, Tatsuguchi et al. (10) showed inhibition of miR-21 in cardiomyocytes using locked nucleic acid–modified antisense oligonucleotides to induce myocyte hypertrophy while overexpression by an miR-21 duplex resulted in a decrease in cardiomyocyte cell size. The basis for these differences is currently unclear. It is notable in this regard that miR-21 has been reported to modulate cell growth both positively and negatively in multiple cancerous cell lines (49, 50) and to promote apoptosis in transformed cells (49, 51).

miRNAs that are downregulated in the hypertrophic and failing heart are also of interest, especially since forced expression of a subset of these prevents hypertrophic cell growth in neonatal rat myocytes (9, 10). It is tempting to speculate that these miRNAs function as negative regulators of cell growth or as regulators of prosurvival pathways such that their downregulation predisposes the heart to pathological remodeling. A major challenge for the future will be to identify the mRNA targets of the miRNAs that participate in cardiac remodeling and to understand the functions of their target miRNAs.

Figure 2
Induction of cardiac hypertrophy and heart failure by miR-195. H&E sections of 2-week-old wild-type and transgenic mice expressing miR-195 under control of the αMHC promoter. In transgenic as compared with wild-type mice, moderate levels of miR-195 expression (26-fold) cause cardiac hypertrophy, and higher levels of expression (29-fold) cause dilated cardiomyopathy with ventricular dilatation and wall thinning. Reproduced with permission from Proceedings of the National Academy of Sciences of the United States of America (8). Scale bar: 2 mm.

Figure 3
Roles of specific miRNAs in cardiac hypertrophy. Stress signals drive a pathological remodeling response of the adult heart, which is characterized by hypertrophy, ventricular dilatation, and fibrosis. miR-208 is required for stress-dependent remodeling and miR-195, which is induced by cardiac stress, is sufficient to drive cardiac remodeling. miR-133 appears to play a negative role in cardiac hypertrophy (5, 6, 8).
Requirement of miR-208 for stress-dependent cardiac growth and gene expression

Encoded within intron 27 of the gene encoding αMHC is miR-208 (5). Like αMHC, miR-208 is expressed specifically in the heart with trace expression in the lung (44). miR-208 is processed out of the αMHC pre-mRNA rather than being transcribed as a separate transcript (5). Intriguingly, however, miR-208 displays a remarkably long half-life of at least 14 days and can thereby exert functions even when αMHC mRNA expression has been downregulated. Although genetic deletion of miR-208 in mice failed to induce an overt phenotype, microarray analysis of hearts from wild-type and miR-208−/− animals at two months of age revealed loss of miR-208 to result in pronounced expression of numerous fast skeletal muscle contractile protein genes, which are normally not expressed in the heart. Thus, it is tempting to speculate that under normal conditions miR-208 is coexpressed with the sole cardiac-specific MHC gene to maintain the cardiomyocyte contractile phenotype by repressing the expression of skeletal muscle genes in the heart.

The most remarkable function of miR-208 was revealed by the aberrant response of miR-208+/− mice to cardiac stress (5). In response to pressure overload by thoracic aortic constriction or signaling by calcineurin (a calcium, calmodulin-dependent phosphatase that drives pathological remodeling of the heart), miR-208+/− mice showed virtually no hypertrophy of cardiomyocytes or fibrosis and were unable to upregulate βMHC expression (Figure 4). In contrast, other stress-responsive genes, such as those encoding atrial natriuretic peptide and B-type natriuretic peptide, were strongly induced in miR-208+/− animals, demonstrating that miR-208 is dedicated specifically to the control of βMHC expression, which can be uncoupled from other fetal cardiac and stress-responsive genes. Clearly, miR-208 is also essential for expression of the genes involved in cardiac fibrosis and hypertrophic growth (Figure 3).

βMHC expression is repressed by thyroid hormone signaling and is upregulated in the hypothyroid state (52). miR-208+/− animals were also resistant to upregulation of βMHC expression following treatment with the thyroid T3 hormone inhibitor propylthiouracil, which induces hypothyroidism. Intriguingly, however, expression of βMHC before birth was normal in miR-208+/− mice, indicating that miR-208 is dedicated specifically to the postnatal regulation of βMHC expression, which coincides with the acquisition of thyroid hormone responsiveness of the gene encoding βMHC.

A clue to the mechanism of action of miR-208 comes from the resemblance of miR-208−/− hearts to hyperthyroid hearts, both of which display a block in βMHC expression, upregulation of stress-response genes, and protection against pathological hypertrophy and fibrosis (52). The upregulation of fast skeletal muscle genes in miR-208−/− hearts also mimics the induction of fast skeletal muscle fibers in the hyperthyroid state (53) and raises the question of whether a similar miRNA-mediated mechanism might govern fast-fiber gene expression in skeletal muscle.

These findings suggest that miR-208 acts, at least in part, by repressing expression of a common component of stress-response and thyroid hormone–signaling pathways in the heart. Among the strongest predicted targets of miR-208 is the thyroid hormone receptor (TR) coregulator TR-associated protein 1 (THRAP1), which can exert positive and negative effects on transcription (54, 55). The TR acts through a negative TRE to repress βMHC expression in the adult heart (44). Thus, the increase in THRAP1 expression in the absence of miR-208 would be predicted to enhance the repressive activity of the TR toward βMHC expression, consistent with the blockade of βMHC expression in miR-208−/− hearts. However, although THRAP1 appears to be a bona fide target of miR-208, these data do not exclude the potential involvement of additional targets in the regulation of βMHC expression (Figure 5).
Since even a subtle shift in the balance of αMHC versus βMHC expression toward βMHC reduces mechanical performance and efficiency of the adult heart (43), it might be of therapeutic value to exploit miR-208 regulation to prevent an increase in βMHC expression during cardiac disease. The cardiac specificity and importance of miR-208 to the cardiac stress response but not to normal cardiac development make miR-208 (and its downstream effectors) an attractive therapeutic target for manipulating βMHC levels.

Roles for miR-1 in cardiac development and contractility

miR-1 is a muscle-specific miRNA that forms a bicistronic cluster with miR-133 (56). The vertebrate genome contains 2 distinct loci for the miR-1/133 cluster with identical mature miRNA sequences, which is likely the result of an ancient genomic duplication. Cardiac expression of both miR-1-1 and miR-1-2 depend on the serum response factor transcription factor (12). While in vitro data suggest a possible role for miR-1 in myocyte hypertrophy (9), its primary function appears to be more related to cardiac development. Cardiac-specific overexpression of miR-1 in the embryonic heart inhibits cardiomyocyte proliferation and prevents expansion of the ventricular myocardium (12). These abnormalities were ascribed to the translational repression of the basic helix-loop-helix transcription factor Hand2, which is required for ventricular growth (57) although it seems likely that additional miR-1 mRNA targets contribute to the phenotype. On the other hand, targeted deletion of miR-1-2 in mice resulted in 50% lethality, largely due to ventricular-septal defects (4). A large proportion of the surviving mutant animals experienced electrophysiological defects and suffered sudden death, which was attributed to the upregulation of the mRNA encoding the transcription factor Irx5, a direct target of miR-1. Prior studies showed that Irx5 negatively regulates the Kv4.2 potassium channel and is thereby critical for maintaining the ventricular repolarization gradient (58). The surviving miR-1 mutant animals also displayed hyperplasia of the myocardium with persistent nuclear abnormalities were ascribed to the translational repression of the basic helix-loop-helix transcription factor Hand2, which is required for ventricular growth (57) although it seems likely that additional miR-1 mRNA targets contribute to the phenotype.

Table 1

In vivo cardiac phenotypes due to changes in miRNA expression

<table>
<thead>
<tr>
<th>miRNA</th>
<th>System</th>
<th>Phenotype</th>
<th>Postulated target(s)</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>miR-1</td>
<td>Transgenic overexpression</td>
<td>Decrease in cardiomyocyte proliferation</td>
<td>Hand2</td>
<td>10</td>
</tr>
<tr>
<td>miR-195</td>
<td>Transgenic overexpression</td>
<td>Pathological growth and heart failure</td>
<td>Unknown</td>
<td>6</td>
</tr>
<tr>
<td>miR-208</td>
<td>Knockout</td>
<td>Inhibition of stress-induced remodeling</td>
<td>THRAP1</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td></td>
<td>and βMHC upregulation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>miR-208</td>
<td>Transgenic overexpression</td>
<td>βMHC upregulation</td>
<td>THRAP1</td>
<td>3</td>
</tr>
<tr>
<td>miR-1</td>
<td>Knockout</td>
<td>Ventricular septal defect, disturbed</td>
<td>Hand2, Irx5, KCND2</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>electrical conductance, hyperplasia due to</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>increased cell division</td>
<td></td>
<td></td>
</tr>
<tr>
<td>miR-1</td>
<td>Injection (i.v.) of AMO for</td>
<td>Arrhythmogenesis</td>
<td>Kcnj2, GJA1</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>knockdown/overexpression</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>miR-133</td>
<td>Antagomir delivery for knockdown through osmotic pump</td>
<td>Sustained cardiac hypertrophy</td>
<td>RhoA, Cdc-42, Nelf-A/WHSC2</td>
<td>4</td>
</tr>
</tbody>
</table>

AMO, anti-miRNA antisense oligonucleotide; antagomir, antisense RNA oligonucleotide.
into the infarcted myocardium exacerbated arrhythmogenesis, miR-1–specific knockdown resulted in suppressed arrhythmias. These data imply that miR-1 is involved in electrical remodeling and arrhythmias, effects that were attributed to the translational repression of the KCNJ2 and GJA1 channels. KCNJ2 encodes Kir2.1, the main K⁺ channel subunit responsible for regulating the cardiac resting membrane potential (59), while GJA1 encodes connexin 43, the main cardiac gap junction channel responsible for intercellular conductance in the ventricle (60).

The apparent importance of miR-1 in inhibiting myocyte proliferation suggests that strategies that diminish miR-1 expression could be efficacious in cardiac regeneration. However, the finding that increasing or decreasing miR-1 expression causes lethal cardiac arrhythmias highlights not only the exquisite sensitivity of the heart to the levels of expression of this miRNA but also poses significant hurdles to the possible therapeutic manipulation of miR-1 levels in the settings of cardiac conduction abnormalities or myocardial repair.

**Roles for miR-133 in cardiac growth and cardiac conduction**

The miR-133 family consists of 2 homologous miR-133a members, designated 133a-1 and 133a-2, and a nearly homologous miR-133b. While the two 133a miRNAs are expressed as part of the same bicistronic unit with miR-1, miR-133b is expressed as a separate transcript (56). In several recent studies (7, 8, 10) of the dysregulation of miRNAs during cardiac hypertrophy, variable patterns of miR-133 expression were reported; sequence homology among the family members made it difficult to determine the relative expression of individual members of this family.

A recent report found miR-133 to be downregulated in human heart disease as well as in three models of cardiac hypertrophy (6). Interestingly, miR-133 was dysregulated during both physiological and pathological hypertrophy, suggesting it participates in a general hypertrophic program. Overexpression in vitro by infecting both neonatal and adult mouse myocytes with an adenoviral vector expressing miR-133 reduced the hypertrophic response to agonist stimulation. Conversely, in vivo knockdown in mice of miR-133 by infusion of an antisense RNA oligonucleotide appeared sufficient to induce significant hypertrophic growth of the heart with induction of fetal gene expression compared with saline-treated mice (6). These results suggest an active role for miR-133 in the inhibition of cardiac hypertrophy (Figure 3).

While these studies imply that strategies to upregulate miR-133 levels in vivo might serve as a therapy for preventing pathological cardiac growth, the recent demonstration of a correlation between miR-133 overexpression and abnormalities in cardiac electrical activity raises concerns about such a therapeutic approach. Xiao et al. (13) reported miR-133 to play a role in cardiac conductance abnormalities during diabetes by lowering the protein levels of ether-a-go-go-related gene (ERG), which encodes a key K⁺ channel (IKr) responsible for rapid delayed rectifier K⁺ current in cardiac cells. In a rabbit model of diabetes, cardiac expression of miR-133 was dramatically increased, coinciding with a pronounced depression of ERG protein, but not mRNA. Exogenous delivery of miR-133 in myocytes also resulted in downregulation of ERG protein, and an antisense inhibitor of miR-133 abrogated the repressive effect of miR-133 on ERG, indicating the specificity of miR-133 action on ERG expression (13).

**Therapeutic opportunities and challenges**

The obvious importance of miRNAs for cardiac function and dysfunction suggests opportunities for therapeutically exploiting the biology of miRNAs in the settings of congenital and acquired heart disease, especially for cardiac arrhythmias and pathological cardiac remodeling. In considering miRNAs as therapeutic targets, it is important to bear in mind that the rationale for therapeutically targeting miRNAs differs from classical approaches for drug development in which the goal is to develop drugs that are highly specific for a single target (generally a receptor or an enzyme). Because single miRNAs have many targets, modulating the expression or activity of one pathogenic or beneficial miRNA can, in principle, influence an entire gene network and thereby modify complex disease phenotypes. Of course, the broad and as yet poorly understood consequences of modulating miRNA function also pose significant challenges with respect to specificity and possible off-target effects.

The use of chemically modified oligonucleotides to target either a specific miRNA or to disrupt the binding between an miRNA and a specific miRNA target in vivo represents a potentially effective means of inactivating pathological miRNAs. An especially promising approach in this regard is the use of single-stranded RNA oligonucleotides, called antagonirs, which efficiently inactivate miRNAs through complementary base pairing (61, 62). Chemical modification and conjugation to cholesterol have been shown to stabilize and facilitate delivery of antagonirs to tissues following i.v. administration (61).

Another challenge to be overcome in the targeted inhibition of miRNAs comes from the fact that many miRNAs belong to families of closely related or even identical miRNAs, which may be expressed in multiple cell types. Thus, the consequences of targeting an miRNA in tissues other than the diseased tissue need to be considered. Because miRNAs have a multitude of mRNA targets, it may also be important to selectively inactivate the effects of an miRNA on specific targets, without unwanted effects on closely related miRNAs. One potential means of circumventing this lack of gene specificity would be to block miRNA actions in a gene-specific manner by specifically disrupting the binding between an miRNA and its designated binding site. Gene-specific miRNA mimics and miRNA-masking antisense approaches to perturb miRNA-mRNA interactions in vitro have recently been described although the applicability of these approaches still needs to be demonstrated in vivo (63). The possibilities of manipulating miRNAs therapeutically are not limited to the inhibition of pathogenic miRNAs. One can also imagine creating artificial miRNAs with salutary effects by promoting the expression of beneficial gene products (e.g., tumor suppressor proteins).

Many of the challenges to be faced in this field are similar to those faced in gene therapy, such as modes of delivery, specificity, toxicity, reversibility, and regulation. It will be important to design strategies for delivery of antagonirs or inactivating oligonucleotides to specific tissues, perhaps by combining them with tissue-specific homing signals. Methods for regulating and reversing the effects of such synthetic anti-miRNAs will also need to be developed, which is an issue of particular relevance given the stability of antagonirs in vivo.

The biology of miRNAs also promises to provide new insights into the cellular basis of disease. Gene profiling to identify miRNAs that are upregulated in response to the downregulation of a spe-
cific miRNA may allow the identification of unexpected regulators of disease processes and potentially interesting therapeutic targets. In this regard, it will also be important to determine whether miRNAs that respond to cellular stress act through cell type–specific or widely expressed targets to evoke their responses. The latter issue becomes important when considering strategies to therapeutically inactivate specific miRNAs in diseased tissues without affecting more general cellular functions. The distinctive signature patterns of miRNA expression associated with various disease states will also allow for new diagnostics.

Looking to the future

The heart, more than most other organs, is especially sensitive to relatively subtle changes in gene dosage and to gene modifier effects, particularly on developmental pathways. Thus, the ability of miRNAs to fine-tune gene expression programs portends their importance in many facets of cardiac biology. Given the vast number of miRNAs and the profound effects on the heart of the few that have been examined so far (Table 1), it is a virtual certainty that many new and unanticipated roles of miRNAs in the control of normal and abnormal cardiac function are awaiting discovery. Lessons learned from the heart will undoubtedly provide insights into important and as yet unappreciated roles of miRNAs in diverse aspects of development and disease.

Acknowledgments

Work in Eric N. Olson’s laboratory was supported by grants from the NIH and the Donald W. Reynolds Cardiovascular Clinical Research Center. E. van Rooij was supported by a National Scientist Development Grant by the American Heart Association.

Address correspondence to: Eric N. Olson, Department of Molecular Biology, University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Boulevard, Dallas, Texas 75390-9148, USA. Phone: (214) 648-1187; Fax: (214) 648-1196; E-mail: Eric.Olson@utsouthwestern.edu.
expression significantly increase power output of rat cardiac myocyte fragments. Circ. Res. 90:1150-1152.